Fresh Equities
CANNPAL ANIMAL THERAPEUTICS LIMITED

CANNPAL ANIMAL THERAPEUTICS LIMITED

ASX:CP1

Company Information

CannPal Animal Therapeutics Limited (CP1) is a pet pharmaceutical Company that has identified an opportunity to benefit from the rapidly growing medical cannabis sector, by developing standardised and dosage controlled, regulatory approved pharmaceuticals, derived from the cannabis plant. The Company is established to research, develop and commercialise regulatory approved, cannabinoid-derived therapeutics, for the global animal health markets, with an initial focus on cats and dogs, in the United States, Europe, Australia and other emerging global markets.

Type

Listed Company

GICS Sub-Industry

Pharmaceuticals

Head Office

Level 3/43 Bay St, Double Bay NSW 2028, Australia

Pharmaceuticals
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.